Skip to main content

DarioHealth Corp

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

DRIO$2.39+16.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Interim Consolidated Statements of Cash Flows

U.S. dollars in thousands

​​​​​​​
​ · ​ · Six months ended
​ · ​ · June 30,
​ · 2024 · 2023
​​Unaudited
Cash flows from operating activities:​​​​​​
Net loss​$(20,785)​$(29,410)
Adjustments required to reconcile net loss to net cash used in operating activities:​​​​
Stock-based compensation​10,420​10,148
Depreciation and impairment​648​191
Change in operating lease right of use assets​425​135
Amortization of acquired intangible assets​2,516​2,238
Decrease (increase) in trade receivables, net​(247)​1,595
Increase in other accounts receivable, prepaid expense and long-term assets​(1,171)​(476)
Decrease (increase) in inventories​(71)​2,042
Decrease in trade payables​(190)​(871)
Decrease in other accounts payable and accrued expenses​(3,034)​(865)
Decrease in deferred revenues​(224)​(531)
Change in operating lease liabilities​(417)​(90)
Change in fair value of warrant liability​(12,643)​—
Non-Cash financial expenses​204​1,501
Other​96​—
​​​​​​​
Net cash used in operating activities​(24,473)​(14,393)
​​​​​​​
Cash flows from investing activities:​​
Purchase of property and equipment​(85)​(220)
Purchase of short-term investments​​—​​(4,996)
Proceeds from redemption of short-term investments​​—​​5,033
Payments for business acquisitions, net of cash acquired​​(8,796)​​—
​​​​​​​
Net cash used in investing activities​(8,881)​(183)
​​​​​​​
Cash flows from financing activities:​​​​
Proceeds from issuance of common stock, net of issuance costs​​-​​1,410
Proceeds from issuance of preferred stock, net of issuance costs​20,206​14,868
Proceeds from borrowings on credit agreement​​—​​29,604
Repayment of long-term loan​​—​​(27,833)
​​​​​​​
Net cash provided by financing activities​20,206​18,049
​​​​​​​
Increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents​(13,148)​3,473
Effect of exchange rate differences on cash, cash equivalents and restricted cash and cash equivalents​​(48)​​—
Cash, cash equivalents and restricted cash and cash equivalents at beginning of period​36,797​49,470
Cash, cash equivalents and restricted cash and cash equivalents at end of period​$23,601​$52,943
Supplemental disclosure of cash flow information:​​​
Cash paid during the period for interest on long-term loan​$1,972​$2,044
Non-cash activities:​​​
Right-of-use assets obtained in exchange for lease liabilities​$428​$14

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.